Keyoumars Soltani to Disease Progression
This is a "connection" page, showing publications Keyoumars Soltani has written about Disease Progression.
Connection Strength
0.021
-
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
Score: 0.021